Panagora Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Panagora Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,895	Closed	-$100K	–	3129
2020 Q3	$100K	Buy	+2,895	New	+$61.7K	﹤0.01%	1797
2018 Q1	–	Sell	-2,559	Closed	-$97K	–	2435
2017 Q4	$97K	Buy	+2,559	New	+$82.6K	﹤0.01%	1887
2016 Q1	–	Sell	-6,375	Closed	-$118K	–	2369
2015 Q4	$118K	Buy	+6,375	New	+$118K	﹤0.01%	1754

Panagora Asset Management's AIMT Position: Q4 2020 in Review

Panagora Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,895 shares — an estimated $100K sold.

Panagora Asset Management first reported a position in AIMT in Q4 2015 and held it in 3 quarters. The position peaked at $118K in Q4 2015. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Panagora Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Panagora Asset Management sold 2,895 Aimmune Therapeutics shares in Q4 2020, an estimated $100K.
Panagora Asset Management first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 3 quarters.
Panagora Asset Management's Aimmune Therapeutics position peaked at $118K in Q4 2015.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Panagora Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.